Impact of Obstructive Sleep Apnea and Triglyceride Glucose Index on Cardiovascular Events in Acute Coronary Syndrome Patients: A Post-Hoc Analysis of the OSA-ACS Study

阻塞性睡眠呼吸暂停和甘油三酯葡萄糖指数对急性冠脉综合征患者心血管事件的影响:OSA-ACS研究的事后分析

阅读:3

Abstract

BACKGROUND: Obstructive sleep apnea (OSA) is highly prevalent in patients with acute coronary syndrome (ACS). The triglyceride glucose (TyG) index is considered closely linked to cardiovascular risk. However, the relationship between OSA, TyG index, and cardiovascular outcomes in ACS patients remains unclear. Hence, this study aimed to examine the effects of OSA and the TyG index on cardiovascular outcomes in ACS patients. METHODS: This post-hoc analysis included 1853 patients from the OSA-ACS project, a single-center prospective cohort study that enrolled ACS patients admitted between January 2015 and December 2019. OSA was defined as an apnea-hypopnea index of ≥15 events/hour. The primary endpoint was major adverse cardiovascular and cerebrovascular events (MACCE). Multivariable Cox regression models were used to evaluate the impact of OSA on cardiovascular events across the TyG index categories. RESULTS: OSA was present in 52.5% of the participants, with a mean TyG index of 9.02 ± 0.68. Over a median follow-up of 35.1 (19.0-43.5) months, OSA was significantly associated with a heightened risk of MACCE (adjusted hazard ratio (aHR): 1.556; 95% confidence interval (CI): 1.040-2.326; p = 0.031) in the high TyG group within the fully adjusted model, along with elevated risk of hospitalization for unstable angina (aHR: 1.785; 95% CI: 1.072-2.971; p = 0.026). No significant associations were observed between OSA and MACCE in the low and moderate TyG groups. CONCLUSIONS: This analysis demonstrates that OSA significantly increases the risk of adverse cardiovascular events in ACS patients with a high TyG index, underscoring the importance of routine OSA screening in these high-risk ACS patients to optimize cardiovascular risk stratification and personalize treatment strategies. THE CLINICAL TRIAL REGISTRATION: NCT03362385, https://clinicaltrials.gov/expert-search?term=NCT03362385.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。